121 related articles for article (PubMed ID: 1596303)
1. Increased serum apolipoprotein(a) in patients with chronic renal failure treated with continuous ambulatory peritoneal dialysis.
Murphy BG; McNamee P; Duly E; Henry W; Archbold P; Trinick T
Atherosclerosis; 1992 Mar; 93(1-2):53-7. PubMed ID: 1596303
[TBL] [Abstract][Full Text] [Related]
2. The uremic dyslipidemia: a cross-sectional and longitudinal study.
Avram MM; Goldwasser P; Burrell DE; Antignani A; Fein PA; Mittman N
Am J Kidney Dis; 1992 Oct; 20(4):324-35. PubMed ID: 1415199
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis.
Attman PO; Samuelsson OG; Moberly J; Johansson AC; Ljungman S; Weiss LG; Knight-Gibson C; Alaupovic P
Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020
[TBL] [Abstract][Full Text] [Related]
4. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis.
Kronenberg F; König P; Neyer U; Auinger M; Pribasnig A; Lang U; Reitinger J; Pinter G; Utermann G; Dieplinger H
J Am Soc Nephrol; 1995 Jul; 6(1):110-20. PubMed ID: 7579063
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal survey of apolipoproteins and atherogenic risk in hemodialysis and continuous ambulatory peritoneal dialysis patients.
Burrell D; Antignani A; Fein PA; Goldwasser P; Mittman N; Avram MM
ASAIO Trans; 1990; 36(3):M331-5. PubMed ID: 2123635
[TBL] [Abstract][Full Text] [Related]
6. Serum lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients.
Kimak E; Solski J
Ren Fail; 2002 Mar; 24(2):187-95. PubMed ID: 12071592
[TBL] [Abstract][Full Text] [Related]
7. Serum lipoprotein (a) concentrations in patients undergoing continuous ambulatory peritoneal dialysis.
Anwar N; Bhatnagar D; Short CD; Mackness MI; Durrington PN; Prais H; Gokal R
Nephrol Dial Transplant; 1993; 8(1):71-4. PubMed ID: 8381941
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease.
Kim SB; Yang WS; Kang ES; Min WK; Park JS
Perit Dial Int; 1997; 17(3):236-42. PubMed ID: 9237283
[TBL] [Abstract][Full Text] [Related]
9. Lipids, lipoproteins and apolipoproteins abnormalities in patients undergoing dialysis.
Yang X; Wang H; Zhu Z; Deng A
J Tongji Med Univ; 1997; 17(2):126-8. PubMed ID: 9639806
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein(a) phenotypes and lipoprotein(a) concentrations in patients with renal failure.
Milionis HJ; Elisaf MS; Tselepis A; Bairaktari E; Karabina SA; Siamopoulos KC
Am J Kidney Dis; 1999 Jun; 33(6):1100-6. PubMed ID: 10352198
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular risk factors in diabetic patients undergoing continuous ambulatory peritoneal dialysis.
Babazono T; Miyamae M; Tomonaga O; Omori Y
Adv Perit Dial; 1996; 12():120-5. PubMed ID: 8865885
[TBL] [Abstract][Full Text] [Related]
12. Lipids, lipoproteins and apolipoproteins A-I and B and apolipoprotein losses in continuous ambulatory peritoneal dialysis.
Steele J; Billington T; Janus E; Moran J
Atherosclerosis; 1989 Sep; 79(1):47-50. PubMed ID: 2803346
[TBL] [Abstract][Full Text] [Related]
13. Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis.
Dieplinger H; Schoenfeld PY; Fielding CJ
J Clin Invest; 1986 Apr; 77(4):1071-83. PubMed ID: 3082933
[TBL] [Abstract][Full Text] [Related]
14. [Alterations of Lp (a) lipoprotein in patients with chronic renal failure treated by continuous ambulatory peritoneal dialysis].
Takegoshi T; Kitoh C; Shimada T; Kawai K; Yamazaki Y; Mabuchi H
Nihon Jinzo Gakkai Shi; 1993 Jun; 35(6):757-63. PubMed ID: 8377289
[TBL] [Abstract][Full Text] [Related]
15. Increased activity of plasma cholesteryl ester transfer protein in children with end-stage renal disease receiving continuous ambulatory peritoneal dialysis.
Asayama K; Hayashibe H; Mishiku Y; Honda M; Ito H; Nakazawa S
Nephron; 1996; 72(2):231-6. PubMed ID: 8684532
[TBL] [Abstract][Full Text] [Related]
16. Protein loss and genetic polymorphism of apolipoprotein(a) modulate serum lipoprotein(a) in CAPD patients.
Wanner C; Bartens W; Walz G; Nauck M; Schollmeyer P
Nephrol Dial Transplant; 1995; 10(1):75-81. PubMed ID: 7724034
[TBL] [Abstract][Full Text] [Related]
17. Increased plasma lipoprotein(a) in continuous ambulatory peritoneal dialysis is related to peritoneal transport of proteins and glucose.
Heimbürger O; Stenvinkel P; Berglund L; Tranoeus A; Lindholm B
Nephron; 1996; 72(2):135-44. PubMed ID: 8684516
[TBL] [Abstract][Full Text] [Related]
18. Effect of dialysis type on serum lipids, apolipoproteins, and lipoproteins.
Kanbay M; Delibasi T; Kaya A; Aydogan T; Koca C; Akcay A; Duranay M; Yigitoglu R
Ren Fail; 2006; 28(7):567-71. PubMed ID: 17050239
[TBL] [Abstract][Full Text] [Related]
19. Ischemic heart disease, serum cholesterol, and apolipoproteins in CAPD.
Gault MH; Longerich L; Prabhakaran V; Purchase L
ASAIO Trans; 1991; 37(3):M513-4. PubMed ID: 1751258
[TBL] [Abstract][Full Text] [Related]
20. [Lipoprotein (a) in children with end stage renal failure on maintenance hemodialysis and continuous ambulatory peritoneal dialysis].
Zwolińska D; Szprynger K
Przegl Lek; 1997; 54(5):320-3. PubMed ID: 9380806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
